Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial

• Published in: JAMA psychiatry (Chicago, Ill.) Vol. 77; no. 7; p. 674
• Main Authors: Voineskos, Aristotle N, Mulsant, Benoit H, Dickie, Erin W, Neufeld, Nicholas H, Rothschild, Anthony J, Whyte, Ellen M, Meyers, Barnett S, Alexopoulos, George S, Hoptman, Matthew J, Lerch, Jason P, Flint, Alastair J
• Format: Journal Article
• Language: English
• Published: United States 01.07.2020
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents - pharmacology; Cerebral Cortex - diagnostic imaging; Cerebral Cortex - drug effects; Cerebral Cortex - pathology; Depressive Disorder, Major - diagnostic imaging; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - pathology; Diffusion Tensor Imaging; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine - pharmacology; Outcome Assessment, Health Care; Psychotic Disorders - diagnostic imaging; Psychotic Disorders - drug therapy; Psychotic Disorders - pathology; Sertraline - pharmacology; White Matter - diagnostic imaging; White Matter - drug effects; White Matter - pathology; Young Adult
• ISSN: 2168-6238
• DOI: 10.1001/jamapsychiatry.2020.0036

Prescriptions for antipsychotic medications continue to increase across many brain disorders, including off-label use in children and elderly individuals. Concerning animal and uncontrolled human data suggest antipsychotics are associated with change in brain structure, but to our knowledge, there are no controlled human studies that have yet addressed this question. To assess the effects of antipsychotics on brain structure in humans. Prespecified secondary analysis of a double-blind, randomized, placebo-controlled trial over a 36-week period at 5 academic centers. All participants, aged 18 to 85 years, were recruited from the multicenter Study of the Pharmacotherapy of Psychotic Depression II (STOP-PD II). All participants had major depressive disorder with psychotic features (psychotic depression) and were prescribed olanzapine and sertraline for a period of 12 to 20 weeks, which included 8 weeks of remission of psychosis and remission/near remission of depression. Participants were then were randomized to continue receiving this regimen or to be switched to placebo and sertraline for a subsequent 36-week period. Data were analyzed between October 2018 and February 2019. Those who consented to the imaging study completed a magnetic resonance imaging (MRI) scan at the time of randomization and a second MRI scan at the end of the 36-week period or at time of relapse. The primary outcome measure was cortical thickness in gray matter and the secondary outcome measure was microstructural integrity of white matter. Eighty-eight participants (age range, 18-85 years) completed a baseline scan; 75 completed a follow-up scan, of which 72 (32 men and 40 women) were useable for final analyses. There was a significant treatment-group by time interaction in cortical thickness (left, t = 3.3; P = .001; right, t = 3.6; P < .001) but not surface area. No significant interaction was found for fractional anisotropy, but one for mean diffusivity of the white matter skeleton was present (t = -2.6, P = .01). When the analysis was restricted to those who sustained remission, exposure to olanzapine compared with placebo was associated with significant decreases in cortical thickness in the left hemisphere (β [SE], 0.04 [0.009]; t34.4 = 4.7; P <.001), and the right hemisphere (β [SE], 0.03 [0.009]; t35.1 = 3.6; P <.001). Post hoc analyses showed that those who relapsed receiving placebo experienced decreases in cortical thickness compared with those who sustained remission. In this secondary analysis of a randomized clinical trial, antipsychotic medication was shown to change brain structure. This information is important for prescribing in psychiatric conditions where alternatives are present. However, adverse effects of relapse on brain structure support antipsychotic treatment during active illness. ClinicalTrials.gov Identifier: NCT01427608.